Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-06-27
2006-06-27
Helms, Larry R. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S155100, C424S156100, C424S181100, C530S387100, C530S388150, C530S388850, C530S391700, C435S069600, C800S006000
Reexamination Certificate
active
07067131
ABSTRACT:
The present invention relates generally to the generation and characterization of anti-MUC18 monoclonal antibodies. The invention further relates to the use of such anti-MUC18 antibodies in the diagnosis and treatment of disorders associated with increased activity of MUC18, in particular, tumors, such as melanomas.
REFERENCES:
patent: 4735210 (1988-04-01), Goldenberg
patent: 5101827 (1992-04-01), Goldenberg
patent: 5102990 (1992-04-01), Rhodes
patent: 5466468 (1995-11-01), Schneider et al.
patent: 5648471 (1997-07-01), Buttram et al.
patent: 5697901 (1997-12-01), Eriksson
patent: 5800820 (1998-09-01), Maione
patent: 6024956 (2000-02-01), Matsushima et al.
patent: 6133426 (2000-10-01), Gonzalez et al.
patent: 6150584 (2000-11-01), Kucherlapati et al.
patent: 6229048 (2001-05-01), Mazur et al.
patent: 6342220 (2002-01-01), Adams et al.
patent: 6342221 (2002-01-01), Thorpe et al.
patent: 2003/0068319 (2003-04-01), Bar-Eli
patent: 0 710 719 (1996-05-01), None
patent: WO 98/24893 (1998-06-01), None
patent: WO 00/76310 (2000-12-01), None
patent: WO 02/077172 (2002-10-01), None
patent: WO 03/057006 (2003-07-01), None
Jain R. K. Scientific American, 271(1):58-65, Jul. 1994.
Dillman R. O. Annals of Internal Medicine, 111:592-603, 1989.
Weiner L. M. Seminars in Oncology, 26 (4 Suppl 12):41-50, Aug. 1999.
Dillman, R. O. Clinical Oncology, 12(7):1497-1515, 1994.
Anfosso et al., “Activation of Human Endothelial Cells via S-Endo-1 Antigen (CD146) Stimulates the Tyrosine Phosphorylation of Focal Adhesion Kinase p125FAK,”J. Bio. Chem., 273(41):26852-26856 (1998).
Bani et al., “Multiple Features of Advanced Melanoma Recapitulated in Tumorigenic Variants of Early Stage (Radial Growth Phase) Human Melanoma Cell Lines: Evidence for a Dominant Phenotype1,”Cancer Res., 56:3075-3086 (1996).
Bar-Eli, M., “Role of AP-2 in tumor growth and metastasis of human melanoma,”Cancer and Metastasis Reviews, 18:377-385 (1999).
Frankel et al., “Cell Surface Receptor-Targeted Therapy of Acute Myeloid Leukemia: A Review,”Cancer Biotherapy&Radiopharmaceuticals, 15(5):459-476 (2000).
Hedrick et al., “The DCC gene product in cellular differentiation and colorectal tumorigenesis,”Genes&Development, 8:1174-83 (1994).
Holzmann et al. “Tumor Progression in Human Malignant Melanoma: Five Stages Defined by Their Antigenic Phenotypes,”Int. J. Cancer, 39:466-471 (1987).
Jean et al., “Regulation of tumor growth and metastasis of human melanoma by the CREB transcription factor family,”Molecular and Cellular Biochemistry, 212:19-28 (2000).
Johnson, J.P. “Cell adhesion molecules in the development and progression of malignant melanoma,”Cancer and Metastasis Reviews, 18: 345-357 (1999).
Johnson, J.P. et al., “Melanoma Progression-Associated Glycoprotein MUC18/MCAM Mediates Homotypic Cell Adhesion Through Interaction with a Heterophilic Ligand,”Int. J. Cancer, 73:769-774 (1997).
Junghans et al.,Cancer Chemotherapy and Biotherapy: Principals and Practice, pp. 655-689 (2d ed., Chabner and Longo, eds., Lippincott Raven 1996).
Knoll et al., “Targeted Therapy of Experimental Renal Cell Carcinoma with a Novel Conjugate of Monoclonal Antibody 138H11 and Calicheamicin θI11,”Cancer Res., 60:6089-6094 (2000).
Lai et al., “Two forms of 1B236/myelin-associated glycoprotein, a cell adhesion molecule for postnatal neural development, are produced by alternative splicing,”Proc. Natl. Acad. Sci. USA, 84:4337-4341 (1987).
Lehmann, J.M. et al., “Discrimination Between Benign and Malignant Cells of Melanocytic Lineage by Two Novel Antigens, a Glycoprotein with a Molecular Weight of 113,000 and a Protein with a Molecular Weight of 76,0001”Cancer Res., 47:841-845 (1987).
Lehmann, J.M. et al, “MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neutral cell adhesion molecules of the immunoglobulin superfamily”Proc. Natl. Acad. Sci. USA, 86:9891-9895 (1989).
Liu et al., “Eradicaton of large colon tumor xenografts by targeted delivery of maytansinoids,”Proc. Natl. Acad. Sci. USA, 93:8618-8623 (1996).
Luca, M. “Direct correlation between MUC18 expression and metastatic potential of human melanoma cells,”Melanoma Res., 3:35-41 (1993).
Mandler et al., “Immunoconjugates of Geldanamycin and Anti-HER2 Monoclonal Antibodies: Antiproliferative Activity on Human Breast Carcinoma Cell Lines,”J. Natl. Cancer Inst., 92(19):1573-1581 (2000).
Ota et al., “Antitumor effect of monoclonal antibody-carboplatin conjugates in nude mice bearing human ovarian cancer cells,”Int. J. Clin. Oncol., 4:236-240 (1999).
Owens et al., “Organization of the neural cell adhesion molecule (N-CAM) gene: Alternative exon usage as the basis for different membrane-associated domains,”Proc. Natl. Acad. Sci. USA, 84:294-298 (1987).
Pickl, W.F. et al., “MUC18/MCAM (CD146), An Activation Antigen of Human T Lymphocytes,”J. Immunol., 158:2107-2115 (1997).
Pourquiè et al., “BEN, a surface glycoprotein of the immunoglobulin superfamily, is expressed in a variety of developing systems,”Proc. Natl. Acad. Sci., USA, 89:5261-5265 (1992).
Satyamoorthy, K. et al., “Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication,”Oncogene, 20:4676-4684 (2001).
Schlagbauer-Wadl, et al., “Influence of MUC18/MCAM/CD146 expression on human melanoma growth and metastasis in scid mice,”Int. J. Cancer, 81:951-955 (1999).
Sers et al., Genomic organization of the melanoma-associated glycoprotein MUC18: Implications for the evolution of the immunoglobulin domains,Proc. Natl. Acad. Sci. USA, 90:8514-8518 (1993).
Sers et al., “MUC18, a Melanoma-Progression Associated Molecule, and Its Potential Role in Tumor Vascularization and Hematogenous Spread1,”Cancer Research, 54:5689-5694 (1994).
Shih et al., “Expression of melanoma cell adhesion molecule in intermediate trophoblast,”Lab. Invest., 75(3):377-388 (1996).
Shih et al., “Isolation and Functional Characterization of the A32 Melanoma-associated Antigen1,”Cancer Res., 54:2514-2520 (1994).
Shih et al, “The Cell-Cell Adhesion Receptor Mel-CAM Acts As a Tumor Suppressor in Breast Carcinoma,”Am. J. Pathol., 151(3):745-751 (1997).
Shih et al., “Melanoma Cell-Cell Interactions Are Mediated through Heterophilic Mel-CAM/Ligand Adhesion1,”Cancer Res., 57:3835-3840 (1997).
Shih et al., “Diagnostic and Biological Implications of Mel-CAM Expression in Mesenchymal Neoplasms,”Clinical Cancer Res., 2:569-575 (1996).
Taira et al., “Molecular Cloning and Functional Expression of Gicerin, a Novel Cell Adhesion Molecule That Binds to Neurite Outgrowth Factor,”Neuron, 12: 861-872 (1994).
Xie et al., “Expression of MCAM/MUC18 by Human Melanoma Cells Leads to Increased Tumor Growth and Metastasis1,”Cancer Res., 57:2295-2303 (1997).
Mills et al., “Fully Human Antibodies to MCAM/MUC18 Inhibit Tumor Growth and Metastasis of Human Melanoma1,”Cancer Research, 62: 5106-5114 (2002).
Higuchi et al., Cyclic AMP Enhances the Expression of an Extravillous Trophoblast Marker, Melanoma Cell Adhesion Molecule, in Choriocarcinoma Cell JEG3 and Human Chorionic Villous Explant Cultures,Molecular Human Reproduction, 9: 359-366 (2003).
Mills L, et al.Cancer Research, 62:5106-5114, Sep. 2002.
Pickl, W.F. et al.Journal of Immunology, 158:2107-2115, Mar. 1997.
Sivam, G et al.Cancer Research, 47(12):3169-3173, 1987.
Wimazal, F. et al.Tissue Antigens, 54:499-507, Nov. 1999.
Xie et al.Cancer Research, 57:2295-2303, Jun. 1997.
Arenberg et al. “Inhibition of Interleukin-8 Reduces Tumorigenesis of Human Non-Small Cell Lung Cancer in SCID Mice.”J. Clin. Invest., 97(12):2792-2802 (1996).
Davis, et al. “Transgenic mice as a source of fully human antibodie
Bar-Eli Menashe
Green Larry L.
Gudas Jean
Abgenix, Inc.
Blanchard David J.
Helms Larry R.
Knobbe Martens Olson & Bear LLP
LandOfFree
Methods for using anti-MUC18 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for using anti-MUC18 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for using anti-MUC18 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3678310